...
首页> 外文期刊>Chinese Medicine >Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection
【24h】

Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection

机译:9例癌症患者SARS-COV-2感染患者的临床特征

获取原文
           

摘要

In December 2019, a cluster of pneumonia cases was caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. Cancer patients are a special group, the immunity of them will be suppressed because of various anti-tumor treatments, and the risk of infection will be greatly increased, so we will report clinical features of 9 cancer patients with SARS-CoV-2 infection. 5 (56%) patients were ordinary type, 3 (33%) were severe type, and 1 (11%) was critical type. A total of 8 patients received combined therapy of traditional Chinese medicines and western medicines. From the clinical outcomes of these 8 patients, western combined therapy of traditional Chinese medicine was indeed an effective treatment method. D-dimmer rise, infection index rise, and chest CT(computed tomography) progression may be clinical warning indicators for severe patients, in our study, more 50% of patients had elevated levels of these indicators, but only 44% (including the dead) of patients had received treatment in the intensive care unit. 5 (56%) ordinary type patients had been discharged, while the 1 (11%) critical type patient died 3 days after admission. Cancer comorbidity seems to have no direct relationship with severe events, and the combination of traditional Chinese medicine and western medicine may be effective in the prevention and treatment of novel coronavirus-infected pneumonia (NICP).
机译:2019年12月,中国武汉严重急性呼吸综合征冠状病毒2(SARS-COV-2)造成的肺炎病例。癌症患者是一个特殊的群体,由于各种抗肿瘤治疗,它们的免疫力将被抑制,并且感染的风险将大大增加,因此我们将报告9例患有SARS-COV-2感染的患者的临床特征。 5(56%)患者是普通型,3(33%)是严重的型,1(11%)是临界型。共有8名患者接受了中药和西药的组合治疗。从这8例患者的临床结果来看,西方联合治疗的中药确实是有效的治疗方法。 D-Dimmer上升,感染指数上升和胸部CT(计算机断层扫描)进展可能是严重患者的临床警告指标,在我们的研究中,更多50%的患者患者的水平升高,但只有44%(包括死亡)患者在重症监护病房中接受治疗。 5(56%)普通型患者已排出,而1(11%)临界型患者入院后3天死亡。癌症合并似乎没有与严重事件直接关系,中药和西医的结合可能有效地预防和治疗新型冠状病毒感染的肺炎(NICP)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号